Austar Lifesciences (HKG:6118) expects a profit attributable to the owners between 15 million yuan and 20 million yuan in 2024, against an attributable loss of 113 million yuan logged for 2023, a Monday Hong Kong bourse filing said.

The company attributed the turnaround to a lack of loss from subsidiaries compared with a year ago, an increase in other income, and the group's organizational optimization.

Shares of the company closed nearly 2% higher on Tuesday.

Price (HKD): $0.57, Change: $+0.0100, Percent Change: +1.79%